4//SEC Filing
Kovner Bruce 4
Accession 0000919574-18-008127
CIK 0001634432other
Filed
Dec 20, 7:00 PM ET
Accepted
Dec 21, 6:16 PM ET
Size
11.6 KB
Accession
0000919574-18-008127
Insider Transaction Report
Form 4
CDK ASSOCIATES, L.L.C.
10% Owner
Transactions
- Purchase
Ordinary Shares, $0.01 par value
2018-12-20$4.00/sh+146,467$585,385→ 6,441,296 total - Purchase
Ordinary Shares, $0.01 par value
2018-12-21$3.95/sh+90,612$357,990→ 6,531,908 total
Kovner Bruce
10% Owner
Transactions
- Purchase
Ordinary Shares, $0.01 par value
2018-12-20$4.00/sh+146,467$585,385→ 6,441,296 total - Purchase
Ordinary Shares, $0.01 par value
2018-12-21$3.95/sh+90,612$357,990→ 6,531,908 total
CAXTON CORP
10% Owner
Transactions
- Purchase
Ordinary Shares, $0.01 par value
2018-12-20$4.00/sh+146,467$585,385→ 6,441,296 total - Purchase
Ordinary Shares, $0.01 par value
2018-12-21$3.95/sh+90,612$357,990→ 6,531,908 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.85 to $4.22 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
- [F2]Following the transactions reported herein, these shares represent (a) 6,196,882 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 335,026 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.82 to $4.10 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Strongbridge Biopharma plc
CIK 0001634432
Entity typeother
Related Parties
1- filerCIK 0001325713
Filing Metadata
- Form type
- 4
- Filed
- Dec 20, 7:00 PM ET
- Accepted
- Dec 21, 6:16 PM ET
- Size
- 11.6 KB